Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Energizer Reports Q1 Earnings Below Street View

Energizer Holdings Inc (NYSE:ENR) reported a first-quarter FY23 sales decline of 10% year-on-year to $765.10 million, missing the consensus of $785.86…
byShivani Kumaresan
February 6, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Energizer Holdings Inc (NYSE:ENR) reported a first-quarter FY23 sales decline of 10% year-on-year to $765.10 million, missing the consensus of $785.86 million.
  • The gross margin for the quarter contracted 220 basis points to 39%.
  • Selling, general and administrative expenses, adjusted, fell 2.2% to $114.1 million.
  • The company held $280.3 million in cash and equivalents as of Dec. 31, 2022.
  • Adjusted EBITDA of $145.6 million decreased 10% Y/Y.
  • Adjusted EPS of $0.72 missed the analyst consensus of $0.76.
  • Outlook: Energizer maintained its forecast for FY23 organic revenue to increase low single digits.
  • The company sees FY23 Adjusted EPS of $3.00 – $3.30 versus the Street view of $3.13.
  • ENR expects Adjusted EBITDA of $585 million – $615 million.
  • Price Action: ENR shares are trading lower by 8.62% at $34.04 on the last check Monday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sonnet BioTherapeutics Announces Pharmacokinetic And Pharmacodynamic Data In A Phase 1 Dose-Escalation Trial Of SON-1010; Says ‘PK data shows an extended half-life of SON-1010 of approximately 112 hours, compared to 12 hours for rhIL-12’

By Bill Haddad
January 19, 9:04 AM
24 healthy volunteers have been dosed in study SB102 to assess the safety, PK, and PD of SON-1010 without the background of prior chemotherapy PK data shows an extended half-life of SON-1010 of approximately 112

SONN